[go: up one dir, main page]

WO2013053008A3 - Molécules liant clec9a - Google Patents

Molécules liant clec9a Download PDF

Info

Publication number
WO2013053008A3
WO2013053008A3 PCT/AU2012/001233 AU2012001233W WO2013053008A3 WO 2013053008 A3 WO2013053008 A3 WO 2013053008A3 AU 2012001233 W AU2012001233 W AU 2012001233W WO 2013053008 A3 WO2013053008 A3 WO 2013053008A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
methods
modulating
dendritic
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2012/001233
Other languages
English (en)
Other versions
WO2013053008A2 (fr
Inventor
Peter Malcolm Colman
Ross Leon Coppel
Peter Edward Czabotar
Mireille Hanna Lahoud
Nicos Anthony Nicola
Antonia Natalie POLICHENI
Kenneth Douglas Shortman
Kirsteen McInnes TULLETT
Jian-Guo Zhang
Jacob Baum
Wilson Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of WO2013053008A2 publication Critical patent/WO2013053008A2/fr
Publication of WO2013053008A3 publication Critical patent/WO2013053008A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'identification de molécules qui lient le marqueur de cellule dendritique désigné Clec9A. La présente invention concerne de nouveaux composés utiles pour le ciblage d'agents thérapeutiques tels que des antigènes de cellules dendritiques. L'invention porte également sur des procédés de modulation d'une réponse immunitaire humorale et/ou à médiation par lymphocytes T audit antigène, sur des procédés d'administration d'un agent cytotoxique à des cellules dendritiques de celui-ci impliquées dans des états maladifs, sur des procédés de modulation de captage et/ou de clairance de cellules présentant une membrane cellulaire brisée, de cellules infectées par un pathogène, de cellules moribondes ou mortes, ou une partie de celles-ci, et sur des procédés de modulation de reconnaissance d'antigène, de traitement et/ou de présentation, ainsi que sur des réponses immunitaires à des substances dérivées de cellules présentant une membrane cellulaire brisée, de cellules infectées par un pathogène, de cellules moribondes ou mortes, ou une partie de celles-ci.
PCT/AU2012/001233 2011-10-14 2012-10-12 Molécules liant clec9a Ceased WO2013053008A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161547632P 2011-10-14 2011-10-14
US61/547,632 2011-10-14
US201261596081P 2012-02-07 2012-02-07
US201261596083P 2012-02-07 2012-02-07
US61/596,083 2012-02-07
US61/596,081 2012-02-07

Publications (2)

Publication Number Publication Date
WO2013053008A2 WO2013053008A2 (fr) 2013-04-18
WO2013053008A3 true WO2013053008A3 (fr) 2013-06-20

Family

ID=48082599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2012/001233 Ceased WO2013053008A2 (fr) 2011-10-14 2012-10-12 Molécules liant clec9a

Country Status (1)

Country Link
WO (1) WO2013053008A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017134302A2 (fr) 2016-02-05 2017-08-10 Orionis Biosciences Nv Agents thérapeutiques ciblés et leurs utilisations
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
WO2018201017A1 (fr) * 2017-04-27 2018-11-01 Washington University Adénovirus ciblant des cellules dendritiques pour la vaccination
EP3665201A4 (fr) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. Agents de liaison au cd8
CN111511764B (zh) 2017-08-09 2024-02-06 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
JP7581048B2 (ja) 2018-03-06 2024-11-12 プレシゲン，インコーポレイテッド ヒトパピローマウイルスワクチンおよびその使用
EP3890773A4 (fr) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. Modulation de lignées de cellules dendritiques
US12502427B2 (en) 2019-03-21 2025-12-23 Lonza Sales Ag Extracellular vesicles for vaccine delivery
US12233356B2 (en) 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles
CN120590542A (zh) 2019-03-28 2025-09-05 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
WO2020215010A1 (fr) 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Compositions d'exosomes et de virus adéno-associés
US20230181758A1 (en) 2019-07-03 2023-06-15 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
EP4117717A1 (fr) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Vésicules extracellulaires pour le traitement de troubles neurologiques
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
CN112724199B (zh) * 2020-12-30 2023-01-24 郑州大学 亲和Clec9a的多肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108215A1 (fr) * 2009-03-23 2010-09-30 The Walter And Eliza Hall Institute Of Medical Research Composés et procédés modulant une réponse immunitaire

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108215A1 (fr) * 2009-03-23 2010-09-30 The Walter And Eliza Hall Institute Of Medical Research Composés et procédés modulant une réponse immunitaire

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AHRENS, S. ET AL.: "F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells", IMMUNITY, vol. 36, no. ISSUE, April 2012 (2012-04-01), pages 635 - 645, XP002693451 *
HOWARD, T. ET AL.: "The 47-kD Protein Increased in Neutrophil Actin Dysfunction With 47- and 89-kD Protein Abnormalities Is Lymphocyte-Specific Protein", BLOOD, vol. 83, no. 1, January 1994 (1994-01-01), pages 231 - 241 *
NESTOR, M. W. ET AL.: "The Actin Binding Domain of betal-Spectrin Regulates the Morphological and Functional Dynamics of Dendritic Spines", PLOS ONE, vol. 6, no. ISS. 1, January 2011 (2011-01-01), pages E16197, XP055071897 *
SANCHO, D. ET AL.: "Identification of a dendritic cell receptor that couples sensing of necrosis to immunity", NATURE, vol. 458, no. 7240, April 2009 (2009-04-01), pages 899 - 903, XP002693445 *
ZHANG, J.-G. ET AL.: "The Dendertic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments", IMMUNITY, vol. 36, no. ISS. 4, April 2012 (2012-04-01), pages 646 - 657, XP002693452 *

Also Published As

Publication number Publication date
WO2013053008A2 (fr) 2013-04-18

Similar Documents

Publication Publication Date Title
WO2013053008A3 (fr) Molécules liant clec9a
MX378807B (es) Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
WO2012159754A3 (fr) Vaccins individualisés pour le cancer
EP4406612A3 (fr) Conjugués anticorps-médicament anti-cd70
TN2015000177A1 (en) Anti-ceacam5 antibodies and uses thereof
EA201790862A1 (ru) Связывающиеся с эритроцитами терапевтические средства
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
WO2013142324A8 (fr) Anticorps neutralisants dirigés contre le vih -1 et leur utilisation
MY174259A (en) Antigen binding protein and its use as addressing product for the treatment of cancer
MX363307B (es) Plataformas para suministro de antigenos.
MX2014009628A (es) Uniones a cdim y sus usos.
WO2014011901A3 (fr) Procédés et compositions pour la délivrance d'agents biologiques
MX392812B (es) Lipidos cationicos de trialquilo y metodos de uso de los mismos.
PH12014500866A1 (en) Immunobinders directed against tnf
WO2011032161A3 (fr) Vaccins dirigés contre les cellules de langerhans
EP4509189A3 (fr) Anticorps anti-fcrn
WO2013040142A3 (fr) Procédés bio-informatiques de détermination de liaisons peptidiques
CO6630164A2 (es) Proteinas que se unen al tnf-a
MX384422B (es) Vector que expresa conjuntamente vacunas y moléculas coestimuladoras
WO2013177593A3 (fr) Identification d'antigènes phosphopeptidiques de cmh de classe i du cancer du sein à l'aide d'une technologie shla et de stratégies d'enrichissement complémentaires
MX2014001626A (es) Preservacion asistida con vacio de productos biologicos, en particular de vacunas.
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
WO2009137871A8 (fr) Procédé permettant de détecter les cellules dont la membrane cellulaire est détériorée, les cellules infectées par un pathogène, les cellules mourantes et les cellules mortes
HK1201176A1 (en) Antigen presenting cancer vaccine
WO2014111840A3 (fr) Peptide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12840003

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12840003

Country of ref document: EP

Kind code of ref document: A2